The TMPRSS2-ERG fusion, present in approximately 50% of prostate cancers, is less common in prostatic intraepithelial neoplasia (PIN), raising questions about whether TMPRSS2-ERG contributes to disease initiation. We identified the translational start site of a common TMPRSS2-ERG fusion and showed that transgenic TMPRSS2-ERG mice develop PIN, but only in the context of PI3-kinase pathway activation. TMPRSS2-ERGpositive human tumors are also enriched for PTEN loss, suggesting cooperation in prostate tumorigenesis.
The TMPRSS2-ERG fusion, present in approximately 50% of prostate cancers, is less common in prostatic intraepithelial neoplasia (PIN), raising questions about whether TMPRSS2-ERG contributes to disease initiation. We identified the translational start site of a common TMPRSS2-ERG fusion and showed that transgenic TMPRSS2-ERG mice develop PIN, but only in the context of PI3-kinase pathway activation. TMPRSS2-ERGpositive human tumors are also enriched for PTEN loss, suggesting cooperation in prostate tumorigenesis.
Recurrent gene fusions involving members of the ETS family of transcription factors occur frequently in human prostate cancer 1 . The TMPRSS2-ERG fusion gene, generated by an interstitial deletion on chromosome 21 or by reciprocal translocation, is the most common rearrangement, found in B50% of localized tumors 1 . The fusion is detected in essentially all the malignant cells within a focus of tumor, supporting a role in disease initiation. However, TMPRSS2-ERG is less commonly found in preneoplastic PIN lesions and, when present, is typically in PIN adjacent to fusion-positive tumor cells 2 . Potential explanations for the relatively low frequency of TMPRSS2-ERG in PIN versus cancer are as follows: (i) TMPRSS2-ERG is not an initiating event, (ii) PIN may not be a reliable precursor lesion to invasive cancer or (iii) PIN is molecularly heterogeneous but TMPRSS2-ERG-driven PIN progresses rapidly to cancer.
We addressed this question by generating transgenic mice expressing the TMPRSS2-ERG fusion in the prostate (Supplementary Methods online). Two ERG isoforms (variants 1 and 2) have been characterized, which differ in the N terminus as well as in the presence of a downstream ERG exon owing to alternative splicing. We designed our TMPRSS2-ERG construct (Fig. 1a) to recreate the most common translocation breakpoints 3 exon array expression profiling data showing relative abundance of variant 2 in TMPRSS2-ERG-positive human tumors 4 . Because of Nterminal truncation of ERG and fusion to noncoding TMPRSS2 sequence, the initiating methionine for ERG translation is removed, raising questions about the translational start site of TMPRSS2-ERG fusion mRNA. To address this issue, we conducted mass spectrometry analysis of the protein product of our TMPRSS2-ERG fusion and recovered five tryptic peptides (Fig. 1b,c , lane 4). The most N-terminal peptide spanned amino acids 58-70 of ERG (nucleotides 358-396), narrowing down the possible start codon to the methionine encoded by nucleotide 304 (Met40 in full-length ERG) or to Met54 at nucleotide 356 (Fig. 1a) . Mutation of the ATG encoding Met40 to AAG substantially impaired translation of the TMPRSS2-ERG protein (Fig. 1c , compare lanes 4 and 5) and, in the context of full-length ERG, eliminated expression of the faster-migrating ERG isoform observed with wild-type ERG overexpression (Fig. 1c , compare lanes 2 and 3). These data implicate Met40 as the principal start site for ERG expression in the TMPRSS2-ERG fusion as well as a potential alternative start site for wild-type ERG expression.
To create transgenic mice, we placed the TMPRSS2-ERG fusion construct under the control of the ARR 2 -Probasin promoter, used in previous models of PIN and prostate cancer [5] [6] [7] . We generated 17 transgene-positive founder animals by injection of the ARR 2 -PB-TMPRSS2-ERG construct into FVB blastocysts (Fig. 1d) , four of which showed stable germline transmission of the transgene. We expanded two lines (43 and 44) that showed robust transgene expression 20-fold greater than endogenous mouse Erg (Fig. 1e) and comparable to that observed in an independently derived mouse expressing full-length ERG variant 1 (ref. 8) . Prostates from TMPRSS2-ERG fusion mice from both lines were harvested at 2, 6, 12 and 14 months and compared with littermate controls. We found no histologic evidence of PIN or invasive cancer in 18 TMPRSS2-ERG mice examined (Fig. 2a) . Although mild dysplasia was seen in some transgene-positive mice, these changes are commonly observed in wild-type mice and cannot be definitively attributed to transgene expression.
These data suggest that TMPRSS2-ERG is insufficient to initiate prostate neoplasia and that cooperating oncogenic lesions are required. Two relatively common abnormalities in human prostate cancer are PTEN loss and MYC amplification, both of which have pathogenic roles in genetically engineered mouse models 5, 9 . We therefore examined a cohort of ERG rearrangement positive and negative human prostate tumors (n ¼ 121) for associated PTEN copy number loss or MYC amplification as measured by high-resolution array-based comparative genome hybridization (aCGH). ERG rearrangement status was determined on the basis of interstitial deletion by aCGH and by exon array-based mRNA expression profiling, which is highly correlated with FISH analysis 10 . Although PTEN inactivation can also occur through loss of expression or point mutation, we determined PTEN status in these tumors by copy number alteration, as this is a common mechanism of PTEN loss and provides robust evidence of gene inactivation. Tumors with PTEN loss were highly enriched for ERG rearrangement (P o 0.002, Fisher's one-sided exact test; Fig. 2b and Supplementary Tables 1-5 online) , consistent with a similar association between reduced PTEN expression (measured by immunohistochemistry) and ERG fusion 8 . A recent report suggests that concurrent ERG rearrangement and PTEN loss in human prostate cancers predicts earlier disease recurrence 11 . In contrast, MYC amplification was not associated with ERG rearrangement (P ¼ 0.56; Fig. 2c ). However, increased MYC mRNA levels, as measured by exon array, were associated with ERG rearrangement (P ¼ 0.0465, data not shown), consistent with recent evidence that MYC is a transcriptional target of TMPRSS2-ERG 12 . Taken together, these data establish that PTEN loss occurs in cooperation with TMPRSS2-ERG fusion; however, ERG rearrangement does not result in selective pressure for MYC amplification.
To test the biological significance of the association between PTEN loss and the TMPRSS2-ERG fusion in human tumors, we crossed our TMPRSS2-ERG mice with Pten +/À mice 9 . At six months of age, all compound mice examined (8 of 8) showed clear histologic evidence of PIN (Fig. 2d) . Notably, one Pten +/À ; TMPRSS2-ERG animal had areas suggestive of microinvasive disease, with attenuation of the periglandular smooth muscle stroma as well as stromal reaction, and inflammation around affected glands ( Fig. 2e and Supplementary Fig. 1  online) . A focus of low-grade PIN was observed in only one out of eight Pten +/À littermate controls where the incidence of PIN at this age is reported to be about 10% 9 . To further explore the interaction with the PI3K pathway, we crossed TMPRSS2-ERG mice with prostate-specific AKT transgenic mice, which develop low-grade PIN but do not progress to invasive cancer even at advanced age 7 . In contrast to eight transgenic AKT littermate controls, eight of eight bigenic mice examined had developed more florid lesions by 10-12 months of age (Fig. 2f) . We also crossed our TMPRSS2-ERG mice to ARR2PB-MYC (Hi-Myc) transgenic mice 5 and found no evidence of cooperativity in eight mice at 3 or 6 months, after which nearly all Hi-Myc mice have developed invasive cancer ( Supplementary Fig. 2 online) . This result is consistent with the failure to detect significant coincidence of TMPRSS2-ERG fusion and MYC amplification in human tumors.
Our finding that TMPRSS2-ERG alone is insufficient to induce prostate neoplasia (or PIN) is in agreement with an independent study published in this issue 8 but contrasts with two other reports that transgenic ERG expression induces PIN at 3-6 months of age 13, 14 . These discrepancies are unlikely to be related to levels of transgene expression. All four models used the ARR2-Pb promoter, and our mice express the transgene at levels comparable to Carver et al. 8 (Fig. 1e) and Klezovitch et al. 13 (data not shown). Our mice differ in the inclusion of upstream untranslated TMPRSS2 sequences in the ERG fusion (which may influence translational efficiency, although we have no evidence for this from transfection experiments) and the use of the variant 2 ERG isoform, which is an abundant allele in human tumors. The difference may lie in interpretation of mouse prostate histology, as the changes reported by Klezovitch et al. 13 and by Tomlins et al. 14 are subtle in comparison to the PIN phenotypes seen in other mouse prostate cancer models. The higher frequency of microinvasion in the ERG; Pten +/À mice in the accompanying report 8 may relate to mouse background because PI3K pathway activation induces a greater degree of proliferation, as measured by K i -67 staining, in C57BL/6 (as used in Carver et al. 8 ) relative to FVB (our model) 15 . Collectively, these data establish cooperativity between PI3K-pathway activation and ERG aberration in induction of PIN, but suggest that additional events are likely required for actual malignancy. Comprehensive human prostate cancer oncogenome studies are needed to fully annotate the frequency of alterations in these and other pathways.
